Last Updated : April 25, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | Darunavir / cobicistat | HIV infection | Withdrawn | |||
TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Pending | |||
TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Pending | |||
TBC | rozanolixizumab | Generalized myasthenia gravis (gMG). | Pending | |||
TBC | talquetamab | Relapsed or refractory multiple myeloma | Pending | |||
TBC | fruquintinib | Metastatic colorectal cancer (mCRC) | Pending | |||
TBC | avapritinib | Advanced Systemic Mastocytosis | Received | |||
TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Received | |||
TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Received | |||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active |